MX2023009867A - Composiciones de neurotoxina para usarse en el tratamiento del dolor de cabeza. - Google Patents

Composiciones de neurotoxina para usarse en el tratamiento del dolor de cabeza.

Info

Publication number
MX2023009867A
MX2023009867A MX2023009867A MX2023009867A MX2023009867A MX 2023009867 A MX2023009867 A MX 2023009867A MX 2023009867 A MX2023009867 A MX 2023009867A MX 2023009867 A MX2023009867 A MX 2023009867A MX 2023009867 A MX2023009867 A MX 2023009867A
Authority
MX
Mexico
Prior art keywords
treating headache
neurotoxin compositions
compositions
methods
neurotoxin
Prior art date
Application number
MX2023009867A
Other languages
English (en)
Inventor
Gregory F Brooks
Adelbert L Stagg
Andrew M Blumenfeld
Original Assignee
Aeon Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeon Biopharma Inc filed Critical Aeon Biopharma Inc
Publication of MX2023009867A publication Critical patent/MX2023009867A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se divulgan composiciones y métodos para usarse en el tratamiento de la migraña, por ejemplo, migraña episódica o crónica, que incluyen métodos con efectos secundarios reducidos y una eficacia comparable o mejorada en comparación con los métodos conocidos en la técnica.
MX2023009867A 2021-02-26 2022-02-25 Composiciones de neurotoxina para usarse en el tratamiento del dolor de cabeza. MX2023009867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163154572P 2021-02-26 2021-02-26
PCT/US2022/018018 WO2022183064A1 (en) 2021-02-26 2022-02-25 Neurotoxin compositions for use in treating headache

Publications (1)

Publication Number Publication Date
MX2023009867A true MX2023009867A (es) 2023-08-29

Family

ID=83049583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009867A MX2023009867A (es) 2021-02-26 2022-02-25 Composiciones de neurotoxina para usarse en el tratamiento del dolor de cabeza.

Country Status (8)

Country Link
EP (1) EP4297870A1 (es)
JP (1) JP2024507589A (es)
KR (1) KR20230152107A (es)
AU (1) AU2022226275A1 (es)
CA (1) CA3212003A1 (es)
IL (1) IL305424A (es)
MX (1) MX2023009867A (es)
WO (1) WO2022183064A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
WO2023287728A1 (en) * 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186464B2 (en) * 2008-05-15 2015-11-17 Allergan, Inc. Dosing injector
US8666498B2 (en) * 2008-10-27 2014-03-04 Serene Medical, Inc. Treatment of headache
US10111938B2 (en) * 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
ES2759478T3 (es) * 2012-03-12 2020-05-11 William J Binder Tratamiento de las cefaleas por migraña con neurotoxina presináptica
AU2020340428A1 (en) * 2019-08-30 2022-03-03 AEON Biopharma, Inc. Neurotoxin compositions for use in treating headache

Also Published As

Publication number Publication date
WO2022183064A1 (en) 2022-09-01
IL305424A (en) 2023-10-01
KR20230152107A (ko) 2023-11-02
AU2022226275A1 (en) 2023-08-31
CA3212003A1 (en) 2022-09-01
EP4297870A1 (en) 2024-01-03
JP2024507589A (ja) 2024-02-20

Similar Documents

Publication Publication Date Title
MX2022002489A (es) Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea.
MX2023009867A (es) Composiciones de neurotoxina para usarse en el tratamiento del dolor de cabeza.
MX2021005767A (es) Composiciones de nanoemulsiones que tienen una permeabilidad mejorada.
EP4339287A3 (en) Modified cells and methods of therapy
MX349773B (es) Uso de fungicidas sintéticos y biológicos en combinación para controlar hongos dañinos.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
NZ739133A (en) Cellular targeted active ingredient delivery system
MX2018008493A (es) Metodo para tratar una afeccion cutanea y composiciones de este.
CR20210573A (es) Moléculas de unión a tigit y pd-1 / tigit
MX2022000726A (es) Anticuerpos inmunomoduladores y metodos de uso de los mismos.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2021005395A (es) Terapia del cáncer con células inmunitarias anti-liv1.
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
MX2016010259A (es) Construcciones de variantes de sirp-alfa y sus usos.
ZA202209970B (en) Neurotoxin compositions for use in treating cardiovascular disorders
PH12020550476A1 (en) Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration
JOP20220248A1 (ar) التراكيب التي تشتمل على أملاح النيكوتين و/أو النيكوتين والرش بالموجات فوق الصوتية للتركيبات المشتملة على أملاح النيكوتين و/أو النيكوتين
MX2023007032A (es) Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
MX2019014027A (es) Uso de glutamina sintetasa para tratar hiperamonemia.
MX2022002367A (es) Composiciones de neurotoxinas para usarse en el tratamiento de neurologicos y trastornos psiquiatricos.
WO2018081817A3 (en) Targeting microrna-101-3p in cancer therapy
MX2022002853A (es) Composiciones de neurotoxina para uso en el tratamiento de la gastroparesia.
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.